ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.110,38
-0,16%
S&P 500
5.667,20
0,64%
US Dollar vs BRL
5,4313
-0,31%
Bitcoin
65.003,92
0,23%
Brent Oil
83,225
-1,32%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nightstar Therapeutics Plc ADS (NITE)

  7. Nightstar Therapeutics Plc ADS (NITE) Notícias

NITE

Nightstar Therapeutics Plc ADS (NITE)

Nightstar Therapeutics Plc ADS
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NITE
DataHoraFonteTítuloCódigoCompanhia
21/01/201010:00PR Newswire (US)Knight Capital Group Releases December 2009 Volume StatisticsNASDAQ:NITENightstar Therapeutics Plc ADS
21/01/201009:00PR Newswire (US)Knight Capital Group Announces Consolidated Earnings of $0.44 Per Diluted Share and Earnings From Continuing Operations of $0.45NASDAQ:NITENightstar Therapeutics Plc ADS
20/01/201019:15PR Newswire (US)Knight Capital Group, Inc. Reports Inducement Grants Under NASDAQ Marketplace Rule 5635NASDAQ:NITENightstar Therapeutics Plc ADS
14/01/201018:50Dow Jones NewsDespite LaBranche's Exit, NYSE Sees Life In Specialist ModelNASDAQ:NITENightstar Therapeutics Plc ADS
11/01/201011:31Edgar (US Regulatory)Current report filing (8-K)NASDAQ:NITENightstar Therapeutics Plc ADS
11/01/201011:30PR Newswire (US)Knight Libertas Appoints Sean Dowd as Managing Director, Co-Head of U.S. Credit SalesNYSE:NITE
05/01/201020:37Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NITENightstar Therapeutics Plc ADS
05/01/201013:00PR Newswire (US)Sidoti & Company Reveals Three Keys to Micro Cap Investing for 2010NASDAQ:NITENightstar Therapeutics Plc ADS
05/01/201006:30PR Newswire (US)Knight Libertas UK Appoints Ron Thompson as Managing Director, Global Head of ABS StrategyNASDAQ:NITENightstar Therapeutics Plc ADS
14/12/200914:27Dow Jones NewsUPDATE: Schwab Warns On 4Q Profit, Cites Fee Waivers, Trading DropNASDAQ:NITENightstar Therapeutics Plc ADS
14/12/200910:30PR Newswire (US)Knight Capital Group Releases November 2009 Volume StatisticsNASDAQ:NITENightstar Therapeutics Plc ADS
09/12/200915:43Dow Jones NewsLive Blogging Of Goldman Conference: Knight Capital CEO SpeaksNASDAQ:NITENightstar Therapeutics Plc ADS
08/12/200911:30Business WireKnight Capital Group and ISE Announce Knight’s Purchase of Competitive Market Maker Trading Rights on ISENASDAQ:NITENightstar Therapeutics Plc ADS
07/12/200911:30PR Newswire (US)Knight Capital Group to Present at Goldman Sachs U.S. Financial Services ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
01/12/200912:15PR Newswire (US)Knight Appoints Daniel G. Braun As Managing Director, Head Of Carbon TradingNYSE:NITE
19/11/200912:00PR Newswire (US)Knight Direct's EdgeTrade Algorithmic Suite Ranked # 1 Among Brokerages in Nasdaq Trading Costs Against VWAP for Third ConsecutiNYSE:NITE
18/11/200914:33Dow Jones NewsCORRECT (11/17):As Exchanges Head To Capitol Hill, Some Customers Grow WaryNASDAQ:NITENightstar Therapeutics Plc ADS
18/11/200910:30PR Newswire (US)Knight Libertas Appoints Brian Yelvington as a Director, Fixed Income Research - StrategyNYSE:NITE
17/11/200919:46Dow Jones NewsAs Exchanges Head To Capitol Hill, Some Customers Grow WaryNASDAQ:NITENightstar Therapeutics Plc ADS
16/11/200910:05MarketwiredRidgewaterEquity.com Free Fundamental Sector & Market Research on NITE, TIBX, CTIC, KLAC, BMRN and ETFCNASDAQ:NITENightstar Therapeutics Plc ADS
13/11/200913:07Edgar (US Regulatory)Form 13F Holdings Report (13F-HR)NASDAQ:NITENightstar Therapeutics Plc ADS
13/11/200910:30PR Newswire (US)Knight Capital Group Releases October 2009 Volume StatisticsNASDAQ:NITENightstar Therapeutics Plc ADS
11/11/200905:00PR Newswire (US)Knight Introduces Knight Link: A New Source of Liquidity for EuropeNASDAQ:NITENightstar Therapeutics Plc ADS
06/11/200918:16Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:NITENightstar Therapeutics Plc ADS
05/11/200908:25MarketwiredRothmanResearch.com Completes Analysis on NEM, CXO, FNB, BLC, WDR and NITENASDAQ:NITENightstar Therapeutics Plc ADS
03/11/200919:15PR Newswire (US)Knight and JTVIR to Co-Host Metals and Mining Conference for Institutional Investors November 18-19 In New YorkNASDAQ:NITENightstar Therapeutics Plc ADS
02/11/200919:15PR Newswire (US)Knight Capital Group To Present at Keefe, Bruyette & Woods Securities Brokerage and Market Structure ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
02/11/200906:00PR Newswire (US)Knight Libertas Expands Global Emerging Markets TeamNYSE:NITE
29/10/200909:30PR Newswire (US)Knight Capital Group To Host Annual Analyst And Investor Meeting Monday, November 2, 2009NASDAQ:NITENightstar Therapeutics Plc ADS
27/10/200908:48MarketwiredAnalystChoice.com Gives Technical review on DISCA, ETFC, SGEN, EBAY, HLIT and NITENASDAQ:NITENightstar Therapeutics Plc ADS
 Apresentando as notícias mais relevantes sobre:NASDAQ:NITE

Seu Histórico Recente

BOV
HAGA3
HAGA ON
BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
VVEO3
CM Hospitalar ON
BOV
JFEN3
JOAO FORTES ON
BOV
AMAR3
LOJAS MARISA ON
BOV
GOLL4
GOL PN
BOV
HBOR3
HELBOR ON
BOV
BOBR4
BOMBRIL PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados